Adherence Therapyfor People with Schizophrenia
Keywords:
Adherence therapy, People with SchizophreniaAbstract
The goals of psychiatric nursing for people with schizophrenia are to promote patients to take care of
themselves, to live with their families and to stay happily in their communities. However, manypeople with
schizophrenia have active symptoms such as delusions, hallucinations, disorganized speech, trouble with
thinking and lack of motivation because they do not take their prescribed antipsychotic medication continuously.
As a result, they cannot manage their life skills and need family supports. The reasons for nonadherence are
poor insight, a negative attitude toward medication, medication side effects, and cognitive impairments.
From theliteratures, the Adherence Therapy is an effective brief psychologicalintervention for persons with
schizophrenia on adherence to medication. The process of therapy comprises of 1)exploring patient's beliefs
about treatment, 2) medication problem solving 3) reviewing past experiences of illness and treatment,
4) exploring awareness of benefits of treatment 5) testing patient's beliefs about medication and 6) helping the
patient determine life goals. This therapy is an important guideline for psychotic nurses to promote medication
adherence for schizophrenic patients effectively.
References
Ahmad, I., Khalily, M. T., & Hallahan, B. (2017). Reasons associated with treatment non-adherence in schizophrenia in a Pakistan cohort. Asian Journal of Psychiatry, 30, 39-43. doi:10.1016/j.ajp.2017.07.024.
Bowtell, M., Eaton, S., Thien, K., Bardell-Williams, M., Downey, L., Ratheesh, A., . . . O'Donoghue, B. (2018). Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis. Schizophrenia Research, 195, 231-236. doi:10.1016/j.schres.2017.10.030.
Chien, W. T., Mui, J., Gray, R., & Cheung, E. (2016). Adherence therapy versus routine psychiatric care for people with schizophrenia spectrum disorders: a randomised controlled trial. BMC Psychiatry, 16, 42. doi:10.1186/s12888-016-0744-6.
Chong HY, Teoh SL, Wu DBC, Kotirum S, Chiou CF, & Chaiyakunapruk N. (2016). Global economic burden of schizophrenia: a systematic review. Neuropsychiatric Disease and Treatment, 2016(Issue 1), 357–373. doi:10.2147/NDT.S96649.
Clifford, L., Crabb, S., Turnbull, D., Hahn, L., & Galletly, C. (2020). A qualitative study of medication adherence amongst people with schizophrenia. Archives of Psychiatric Nursing, 34(4), 194–199. doi:10.1016/j.apnu.2020.06.002.
Department of Mental Health, Ministry of Public Health. (2018). Department of Mental Health Annual Report 2015-2018. Nonthaburi: Department of Mental Health. [In Thai].
Dikec, G., & Kutlu, Y. (2016). Effectiveness of adherence therapy for people with schizophrenia in Turkey: A controlled study. Archives of Psychiatric Nursing, 30(2), 249-256. doi:10.1016/j.apnu.2015.11.009.
Dilokthornsakul, P., Thoopputra, T., Patanaprateep, O., Kongsakon, R., & Chaiyakunapruk, N. (2016). Effects of medication adherence on hospitalizations and healthcare costs in patients with schizophrenia in Thailand. SAGE Open Medicine, 4. doi:10.1177/2050312116637026.
Fitryasari, R., Yusuf, A., Nursalam, Tristiana, R. D., & Nihayati, H. E. (2018). Family members' perspective of family resilience's risk factors in taking care of schizophrenia patients. International Journal of Nursing Sciences, 5(3), 255-261. doi:10.1016/j.ijnss.2018.06.002.
Forsman, J., Taipale, H., Masterman, T., Tiihonen, J., & Tanskanen, A. (2019). Adherence to psychotropic medication in completed suicide in Sweden 2006-2013: a forensic-toxicological matched case-control study. European Journal of Clinical Pharmacology, 75(10), 1421-1430. doi:10.1007/s00228-019-02707-z.
Gray, R., Bressington, D., Ivanecka, A., Hardy, S., Jones, M., Schulz, M., . . . Chien, W. T. (2016). Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis. BMC Psychiatry, 16, 90. doi:10.1186/s12888-016-0801-1.
Juntapim, S., & Nuntaboot, K. (2018). Care of patients with schizophrenia in the community. Archives of Psychiatric Nursing, 32(6), 855-860. doi:10.1016/j.apnu.2018.06.011.
Kretchy, I. A., Osafo, J., Agyemang, S. A., Appiah, B., & Nonvignon, J. (2018). Psychological burden and caregiver-reported non-adherence to psychotropic medications among patients with schizophrenia. Psychiatry Research, 259, 289-294. doi:10.1016/j.psychres.2017.10.034.
Laidi, C., Prigent, A., Plas, A., Leboyer, M., Fond, G., Chevreul, K., & Group, F.-S. (2018). Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset. European Neuropsychopharmacology, 28(1), 24–36. doi:10.1016/j.euroneuro.2017.11.020.
Lawrence, R. E., & Dixon, L. (2019). The Challenge of nonadherence in schizophrenia. In F. Victor, & D. Ida. Psychiatric nonadherence : A solutions-based approach (pp. 43-57). Cham, Switzerland: Springer.
Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., . . . Davis, J. M. (2017). Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. American Journal of Psychiatry, 174(10), 927-942. doi:10.1176/appi.ajp.2017.16121358.
Lowtagon, M., & Sukanid, P. (2001). Psychology Ramathibodi (3rd ed.). Bangkok: Beyon Enterprise Company. [In Thai].
Moncrieff, J., Crellin, N. E., Long, M. A., Cooper, R. E., & Stockmann, T. (2019). Definitions of relapse in trials comparing antipsychotic maintenance with discontinuation or reduction for schizophrenia spectrum disorders: A systematic review. Schizophrenia Research. October. doi:10.1016/j.schres.2019.08.035.
Munikanan, T., Midin, M., Daud, T. I. M., Rahim, R. A., Bakar, A. K. A., Jaafar, N. R. N., . . . Baharuddin, N. (2017). Association of social support and quality of life among people with schizophrenia receiving community psychiatric service: A cross-sectional study. Comprehensive Psychiatry, 75, 94-102. doi:10.1016/j.comppsych.2017.02.009.
Phanthunane, P., Vos, T., Whiteford, H., & Bertram, M. (2012). Improving mental health policy in the case of schizophrenia in Thailand: evidence-based information for efficient solutions. BMC Public Health, 12(S2). doi:10.1186/1471-2458-12-s2-a32.
Roberto, P., Brandt, N., Onukwugha, E., Perfetto, E., Powers, C., & Stuart, B. (2017). Adherence to antipsychotic therapy: Association with hospitalization and medicare spending among part D enrollees with schizophrenia. Psychiatric Services, 68(11), 1185-1188. doi:10.1176/appi.ps.201600434.
Schulz, M., Gray, R., Spiekermann, A., Abderhalden, C., Behrens, J., & Driessen, M. (2013). Adherence therapy following an acute episode of schizophrenia: a multi-centre randomised controlled trial. Schizophrenia Research, 146(1-3), 59-63. doi:10.1016/j.schres.2013.01.028
Smith, R. L., Tveito, M., Kyllesø, L., Jukic, M. M., Ingelman-Sundberg, M., Andreassen, O. A., & Molden, E. (2020). Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs – A study based on blood sample analyses from 24,239 patients. European Neuropsychopharmacology. doi:10.1016/j.euroneuro.2020.06.007.
Tham, X. C., Xie, H., Chng, C. M., Seah, X. Y., Lopez, V., & Klainin-Yobas, P. (2016). Factors affecting medication adherence among adults with schizophrenia: A literature review. Archives of Psychiatric Nursing, 30(6), 797-809. doi:10.1016/j.apnu.2016.07.007.
Ucok, A., & Kara, I. A. (2019). Relapse rates following antipsychotic discontinuation in the maintenance phase after first-episode of schizophrenia: Results of a long-term follow-up study. Schizophrenia Research. doi:10.1016/j.schres.2019.10.015.
von Bormann, S., Robson, D., & Gray, R. (2015). Adherence therapy following acute exacerbation of schizophrenia: A randomised controlled trial in Thailand. International Journal of Social Psychiatry, 61(1), 3-9. doi:10.1177/0020764014529099.
World Health Organization. (2003). Adherence to long term therapy: Evidence for action. Retrieved 14 September 2020 from https://www.who.int/chp/knowledge/publications/adherence_full_report.pdf?ua=1.
Yan, T., Greene, M., Chang, E., Hartry, A., Touya, M., & Broder, M. S. (2018). Medication adherence and discontinuation of aripiprazole once-monthly 400 mg (AOM 400) versus oral antipsychotics in patients with schizophrenia or bipolar I disorder: A real-world study using US claims data. Advances in Therapy, 35(10), 1612-1625. doi:10.1007/s12325-018-0785-y.
